CC2000199 / BMS - LARVOL DELTA

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in paediatric patients in Japan (2020-2023). (PubMed, J Med Microbiol) - "Overall resistance rates to penicillin (PEN), cefotaxime, meropenem (MEM) and erythromycin (ERY) were 31.8, 15.9, 18.5 and 88.7%, respectively...Genomic analysis revealed that the predominant genotypes were 15B/C-CC199, 15A-CC63, 24B-CC2754 and 10A-CC5236.Conclusion. Non-vaccine and PEN-, MEM- and ERY-resistant clones, particularly 15A-CC63 and 35B-CC558, were prevalent among paediatric pneumococci in Japan. Even with PCV20, less than half of the IPD isolates were covered; this underscores the need for ongoing genomic surveillance, antimicrobial stewardship and consideration of expanded-valency vaccines targeting additional serotypes, such as 15A and 35B."

Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

CC2000199, a potent and selective androgen receptor ligand-directed degrader (AR LDD) with a dual mechanism of action, exhibits anti-tumor activity in multiple enzalutamide-resistant preclinical models for metastatic castration-resistant prostate cancer (AACR 2025) - "CC2000199 (also called CC-199) is a heterobifunctional ligand‑directed degrader (LDD) that enables CRL4CRBN E3 ligase-dependent ubiquitination and degradation of AR and a close analog of BMS-986365. Indeed, significant tumor volume reductions were achieved by CC-199 in validated models of advanced CRPC and therapy resistant patient-derived xenografts, including those with acquired resistance to ENZ. Collectively, our preclinical data suggest that the AR degrader CC-199 is superior to standard-of-care AR antagonists, such as ENZ, in disease-relevant animal models and ENZ-resistant mCRPC that remain dependent on AR."

Metastases • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FKBP5